GCIA
FOLD

Gabelli & Co Investment Advisers’s Amicus Therapeutics FOLD Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2M Buy
777,340
+291,390
+60% +$4.18M 1.67% 17
2025
Q4 		$6.92M Buy
+485,950
New +$4.77M 1.04% 25

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Gabelli & Co Investment Advisers's FOLD Position: Q1 2026 in Review

Gabelli & Co Investment Advisers increased its Amicus Therapeutics (FOLD) stake by 60% in Q1 2026, buying an estimated $4.18M and bringing the position to 777,340 shares worth $11.2M. The position accounts for 1.67% of the portfolio, ranked #17.

Gabelli & Co Investment Advisers first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Gabelli & Co Investment Advisers held 777,340 shares of Amicus Therapeutics worth $11.2M as of Q1 2026.
  • Gabelli & Co Investment Advisers bought 291,390 Amicus Therapeutics shares in Q1 2026, an estimated $4.18M.
  • Amicus Therapeutics made up 1.67% of Gabelli & Co Investment Advisers's portfolio in Q1 2026, its #17 holding.
  • Gabelli & Co Investment Advisers first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.